Posts Tagged ‘Conference Coverage with Social Media’

Leaders in Pharmaceutical Intelligence Presentation at The Life Sciences Collaborative

Curator: Stephen J. Williams, Ph.D. Website Analytics: Adam Sonnenberg, BSc Leaders in Pharmaceutical Intelligence presented their ongoing efforts to develop an open-access scientific and medical publishing and curation platform to The Life Science Collaborative, an executive pharmaceutical and biopharma networking group in the Philadelphia/New Jersey area.

Our Team


For more information on the Vision, Funding Deals and Partnerships please see our site at


For more information about our Team please see our site at


For more information of LPBI Deals and Partnerships please see our site at


For more information about our BioMed E-Series please see our site at

E-Book Titles by LPBI

LPBI book titles slide Slide8Slide3


For more information on Real-Time Conference Coverage including a full list of Conferences Covered by LPBI please go to

For more information on Real-Time Conference Coverage and a full listing of Conferences Covered by LPBI please go to: Slide7


The Pennsylvania (PA) and New Jersey (NJ) Biotech environment had been hit hard by the recession and loss of anchor big pharma companies however as highlighted by our interviews in “The Vibrant Philly Biotech Scene” and other news outlets, additional issues are preventing the PA/NJ area from achieving its full potential (discussions also with LSC)

Slide9Download the PowerPoint slides here: Presentationlsc


Read Full Post »

Twitter is Becoming a Powerful Tool in Science and Medicine

 Curator: Stephen J. Williams, Ph.D.

Updated 4/2016

Life-cycle of Science 2

A recent Science article (Who are the science stars of Twitter?; Sept. 19, 2014) reported the top 50 scientists followed on Twitter. However, the article tended to focus on the use of Twitter as a means to develop popularity, a sort of “Science Kardashian” as they coined it. So the writers at Science developed a “Kardashian Index (K-Index) to determine scientists following and popularity on Twitter.

Now as much buzz Kim Kardashian or a Perez Hilton get on social media, their purpose is solely for entertainment and publicity purposes, the Science sort of fell flat in that it focused mainly on the use of Twitter as a metric for either promotional or public outreach purposes. A notable scientist was mentioned in the article, using Twitter feed to gauge the receptiveness of his presentation. In addition, relying on Twitter for effective public discourse of science is problematic as:

  • Twitter feeds are rapidly updated and older feeds quickly get buried within the “Twittersphere” = LIMITED EXPOSURE TIMEFRAME
  • Short feeds may not provide the access to appropriate and understandable scientific information (The Science Communication Trap) which is explained in The Art of Communicating Science: traps, tips and tasks for the modern-day scientist. “The challenge of clearly communicating the intended scientific message to the public is not insurmountable but requires an understanding of what works and what does not work.” – from Heidi Roop, G.-Martinez-Mendez and K. Mills

However, as highlighted below, Twitter, and other social media platforms are being used in creative ways to enhance the research, medical, and bio investment collaborative, beyond a simple news-feed.  And the power of Twitter can be attributed to two simple features

  1. Ability to organize – through use of the hashtag (#) and handle (@), Twitter assists in the very important task of organizing, indexing, and ANNOTATING content and conversations. A very great article on Why the Hashtag in Probably the Most Powerful Tool on Twitter by Vanessa Doctor explains how hashtags and # search may be as popular as standard web-based browser search. Thorough annotation is crucial for any curation process, which are usually in the form of database tags or keywords. The use of # and @ allows curators to quickly find, index and relate disparate databases to link annotated information together. The discipline of scientific curation requires annotation to assist in the digital preservation, organization, indexing, and access of data and scientific & medical literature. For a description of scientific curation methodologies please see the following links:

Please read the following articles on CURATION

The Methodology of Curation for Scientific Research Findings

Power of Analogy: Curation in Music, Music Critique as a Curation and Curation of Medical Research Findings – A Comparison

Science and Curation: The New Practice of Web 2.0

  1. Information Analytics

Multiple analytic software packages have been made available to analyze information surrounding Twitter feeds, including Twitter feeds from #chat channels one can set up to cover a meeting, product launch etc.. Some of these tools include:

Twitter Analytics – measures metrics surrounding Tweets including retweets, impressions, engagement, follow rate, …

Twitter Analytics – – determine most impactful # for your Tweets For example, meeting coverage of bioinvestment conferences or startup presentations using #startup generates automatic retweeting by Startup tweetbot @StartupTweetSF.


  1. Tweet Sentiment Analytics

Examples of Twitter Use

A. Scientific Meeting Coverage

In a paper entitled Twitter Use at a Family Medicine Conference: Analyzing #STFM13 authors Ranit Mishori, MD, Frendan Levy, MD, and Benjamin Donvan analyzed the public tweets from the 2013 Society of Teachers of Family Medicine (STFM) conference bearing the meeting-specific hashtag #STFM13. Thirteen percent of conference attendees (181 users) used the #STFM13 to share their thoughts on the meeting (1,818 total tweets) showing a desire for social media interaction at conferences but suggesting growth potential in this area. As we have also seen, the heaviest volume of conference-tweets originated from a small number of Twitter users however most tweets were related to session content.

However, as the authors note, although it is easy to measure common metrics such as number of tweets and retweets, determining quality of engagement from tweets would be important for gauging the value of Twitter-based social-media coverage of medical conferences.

Thea authors compared their results with similar analytics generated by the HealthCare Hashtag Project, a project and database of medically-related hashtag use, coordinated and maintained by the company Symplur.  Symplur’s database includes medical and scientific conference Twitter coverage but also Twitter usuage related to patient care. In this case the database was used to compare meeting tweets and hashtag use with the 2012 STFM conference.

These are some of the published journal articles that have employed Symplur ( data in their research of Twitter usage in medical conferences.

B. Twitter Usage for Patient Care and Engagement

Although the desire of patients to use and interact with their physicians over social media is increasing, along with increasing health-related social media platforms and applications, there are certain obstacles to patient-health provider social media interaction, including lack of regulatory framework as well as database and security issues. Some of the successes and issues of social media and healthcare are discussed in the post Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification.

However there is also a concern if social media truly engages the patient and improves patient education. In a study of Twitter communications by breast cancer patients Tweeting about breast cancer, authors noticed Tweeting was a singular event. The majority of tweets did not promote any specific preventive behavior. The authors concluded “Twitter is being used mostly as a one-way communication tool.” (Using Twitter for breast cancer prevention: an analysis of breast cancer awareness month. Thackeray R1, Burton SH, Giraud-Carrier C, Rollins S, Draper CR. BMC Cancer. 2013;13:508).

In addition a new poll by Harris Interactive and HealthDay shows one third of patients want some mobile interaction with their physicians.

Some papers cited in Symplur’s HealthCare Hashtag Project database on patient use of Twitter include:

C. Twitter Use in Pharmacovigilance to Monitor Adverse Events

Pharmacovigilance is the systematic detection, reporting, collecting, and monitoring of adverse events pre- and post-market of a therapeutic intervention (drug, device, modality e.g.). In a Cutting Edge Information Study, 56% of pharma companies databases are an adverse event channel and more companies are turning to social media to track adverse events (in Pharmacovigilance Teams Turn to Technology for Adverse Event Reporting Needs). In addition there have been many reports (see Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter) that show patients are frequently tweeting about their adverse events.

There have been concerns with using Twitter and social media to monitor for adverse events. For example FDA funded a study where a team of researchers from Harvard Medical School and other academic centers examined more than 60,000 tweets, of which 4,401 were manually categorized as resembling adverse events and compared with the FDA pharmacovigilance databases. Problems associated with such social media strategy were inability to obtain extra, needed information from patients and difficulty in separating the relevant Tweets from irrelevant chatter.  The UK has launched a similar program called WEB-RADR to determine if monitoring #drug_reaction could be useful for monitoring adverse events. Many researchers have found the adverse-event related tweets “noisy” due to varied language but had noticed many people do understand some principles of causation including when adverse event subsides after discontinuing the drug.

However Dr. Clark Freifeld, Ph.D., from Boston University and founder of the startup Epidemico, feels his company has the algorithms that can separate out the true adverse events from the junk. According to their web site, their algorithm has high accuracy when compared to the FDA database. Dr. Freifeld admits that Twitter use for pharmacovigilance purposes is probably a starting point for further follow-up, as each patient needs to fill out the four-page forms required for data entry into the FDA database.

D. Use of Twitter in Big Data Analytics

Published on Aug 28, 2012…

Course: Information 290. Analyzing Big Data with Twitter
School of Information
UC Berkeley

Lecture 1: August 23, 2012

Course description:
How to store, process, analyze and make sense of Big Data is of increasing interest and importance to technology companies, a wide range of industries, and academic institutions. In this course, UC Berkeley professors and Twitter engineers will lecture on the most cutting-edge algorithms and software tools for data analytics as applied to Twitter microblog data. Topics will include applied natural language processing algorithms such as sentiment analysis, large scale anomaly detection, real-time search, information diffusion and outbreak detection, trend detection in social streams, recommendation algorithms, and advanced frameworks for distributed computing. Social science perspectives on analyzing social media will also be covered.

This is a hands-on project course in which students are expected to form teams to complete intensive programming and analytics projects using the real-world example of Twitter data and code bases. Engineers from Twitter will help advise student projects, and students will have the option of presenting their final project presentations to an audience of engineers at the headquarters of Twitter in San Francisco (in addition to on campus). Project topics include building on existing infrastructure tools, building Twitter apps, and analyzing Twitter data. Access to data will be provided.

Other posts on this site on USE OF SOCIAL MEDIA AND TWITTER IN HEALTHCARE and Conference Coverage include:

Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA

Strategy for Event Joint Promotion: 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London

REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

PCCI’s 7th Annual Roundtable “Crowdfunding for Life Sciences: A Bridge Over Troubled Waters?” May 12 2014 Embassy Suites Hotel, Chesterbrook PA 6:00-9:30 PM

CRISPR-Cas9 Discovery and Development of Programmable Genome Engineering – Gabbay Award Lectures in Biotechnology and Medicine – Hosted by Rosenstiel Basic Medical Sciences Research Center, 10/27/14 3:30PM Brandeis University, Gerstenzang 121

Tweeting on 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London

Statistical Analysis of Tweet Feeds from the 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London

1st Pitch Life Science- Philadelphia- What VCs Really Think of your Pitch

What VCs Think about Your Pitch? Panel Summary of 1st Pitch Life Science Philly

How Social Media, Mobile Are Playing a Bigger Part in Healthcare

Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification.

Medical Applications and FDA regulation of Sensor-enabled Mobile Devices: Apple and the Digital Health Devices Market

E-Medical Records Get A Mobile, Open-Sourced Overhaul By White House Health Design Challenge Winners

Read Full Post »

14:00PM – 10/1/2014: Conference Workshop “Conundrums and Conflicts in Licensing & M&A Deals” @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Real Time Media Conference Coverage  –  Business and Scientific Channels: Aviva Lev-Ari, PhD, RN @

14:00PM  “Conundrums and Conflicts in Licensing & M&A Deals” – An interactive workshop considering ethical dilemmas and challenges in biopharmaceutical deal making

Workshop facilitators: 

  • Nigel Borshell, VP,
  • Fintan Walton, Chief Executive, PharmaVentures Ltd

Four groups of three executive are participating at the Workshop on M&A, One member will act as CEO and present the Scenario and the solution

Five different M&A Scenarios will be presented

  • TRANSPARENCY – trust
  • M&A – Consultancy agreement was rejected
  • Licensing a Medical Device permanently in-dwelling – Lifetime revenue per patient $600,000 – licensor proposes cut in royalties and fees for service
  • Licensee is locked in a crippling 40% on royalties

Case #1:


M&A – Consultancy agreement was rejected

Licensing a Medical Device permanently in-dwelling – Lifetime revenue per patient $600,000 – licensor proposes cut in royalties and fees for service – Two parties need to solve

Licensee is locked in a crippling 40% on royalties – Royalties to be renegotiated


Case #2:

TRANSPARENCY – a case of financial exhaustion of funding, transparency is very important

M&A – continue negotiation to pay less

Licensing a Medical Device permanently in-dwelling – Lifetime revenue per patient $600,000 – licensor proposes cut in royalties and fees for service – who own the device? sharing is the solution

Licensee is locked in a crippling 40% on royalties – Incentive for 40% is basis to secure debt


Case #3:

Partnership consideration

M&A – continue with 5% minority shareholder, do accept the consultancy

Licensing a Medical Device permanently in-dwelling – Lifetime revenue per patient $600,000 – licensor proposes cut in royalties and fees for service – if a contract in place on device use — is their a monopoly?

Licensee is locked in a crippling 40% on royalties – Licensee, Board and Originator – try to advance the state to Phase III

Gross sales – not the value added TAX, TAXES ASSESSED ON INCOME DERIVED FROM SALES – CONSISTENCY with business practices – change agreement

Case #4:

not an easy answer, continue with the second proposition of increasing the investment to $50Million

Licensing a Medical Device permanently in-dwelling – Lifetime revenue per patient $600,000 – licensor proposes cut in royalties and fees for service – contractual obligation, while one party request change – split the gap, giant Pharma should not change contract

Licensee is locked in a crippling 40% on royalties – negotiate with originator, fall back position to be sought – option deal


Gross sales – not the value added TAX, TAXES ASSESSED ON INCOME DERIVED FROM SALES – New agreement to increase royalties

Moderator: was it a mistake  – NOT TO TAKE VAT WHEN 99% OF CONTRACTS REQUIRES VAT, no pay of royalties of VAT

time limit beyond 2 years in royalties






Read Full Post »

12:30AM – 10/1/2014: Company Presentations @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Real Time Media Conference Coverage  –  Business and Scientific Channels: Aviva Lev-Ari, PhD, RN @

Early Stage Investment

  • Hakan Goker, Director MS Ventures

– Participation of Corporate creation: 48% of new corp creation in Europe is via VCs

– early stage investment – Entrepreneur

– Serial Investors – what is the valuation process

– large institutions – where are the good fits, challenges in early stage funding?

– early stage involve understanding very complicated Science, acquisition in Pharma – Mechanism effect on Disease in the  past

– in the present public pressure on big Pharma in a therapeutics area – leverage focused R&D via a lower cost investment is done externally

– cash is available

– Pharma Ventures invest NOT in what VCs invests

– BIOTECH is the faster and cheaper pharma

– If financial are sufficient is taking additional external financing smart to do? – Mix sources of finance — are not successful since the 2009. On the venture side it did not apply.

– In Europe companies do get valuation like in the US sometime

  • David Sabow: Head of Life Sciences, Silicon Valley Bank

– trend in Europe

– Super Angels

– Venture Debt – is never welcomed, what are the drivers a reaction to later stage pipeline, or R&D

– Capital is available – concerns: Competitive insight

– increasing value is the name of the game any method works, mix financing source is included


  • Bernd Goergen

– Life sciences engage Super Angels, trend declined corporate

– comparison in financing Europe vs US/UK on information asymmetry

– VCs feel better if a corporate investor is involved

– without European investor hard to get US money

  • Frank Kalkbrenner

– Boston, SF easier to get Early stage investment

– Europe, mainland – Corporate venture funds are active in Netherlands and Germany

– Venture arms of Pharma involved in early stage

– UK and Boston fund are very LOCAL in proximity, no investment is more than 100 miles away

– no shortage of opportunities in Europe, some investments overseas, In UK, In US — so missing in Germany – less experience in commercial negotiation with Universities, Scientific base, Money, People – success requires Professional management — is not abundant in Europe vs UK, US – different cunture in Europe, CEO who failed in Europe is doom, in the US is hard

– 100% of all products and Phase IIa is from internal research, Gene therapy, cant cover internally, investing in external venture gives access to innovation not to be provided inside

– access external innovation, equity investment is one tool, Early investment to become an equity relations

– Big Pharma Venture Arm is a strategic instrument rather than an ROI strategy

– two corporate ventures, two institutional ventures

– later stage development requires ofter institutional investment

– time is money, get additional financing to get to market as soon as you can, even if you are able to finance operations

  • Soren Moller

– difficult market for early investment

– shareholder in Scandinavia: Private investment can be a hurdle

  • Ulf Grawunder, CEO, NBE Therapeutics, GmbH

– difficult to fund Early stage concepts

– Conventional VCs: funding by VCs are worry of the long tern to ROI – ten years on average – pay to Limited Partners

– Private VCs that reinvest in ventures may consider Early Stage

–  Seeking government grants, non diluted, Patents from Universities, Team up with Academic institution to help in value creation, for proof of concept,

– compelling data, academic collaboration, IP protection

– corporate structure need to allow all types of investments: Partners requires equity for very small investment in Switzerland – non dilutive is very important

– partnering to early on requires sharing equity to early

– Option of first refusal not a strategy

– GSK – no interference with pipeline

– Entrepreneur has concern of IP in due diligence  – internal to Pharma research input on external is important

Questions from the Audience

– asset financing vs VCs

– differential valuation







Read Full Post »

11:00AM – 10/1/2014: Scientific Collaborations  @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Real Time Media Conference Coverage  –  Business and Scientific Channels: Aviva Lev-Ari, PhD, RN @

11:00AM – 10/1/2014: Scientific Collaborations

Introductory Speech by: 

  • Ora Dar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, Israel – $70M gov. Budget

– IT is shared and used in collaboration

– Eight companies – 2 stem cells, Virtual Biopsy, Endoscopy

– 25% is from Academia rest from Industry

– Brain stimulation and Monitoring Technologies

– Synergies: with Roche; Pontifax

– collaboration announced 2009: new companies: BioVent, Quiet Therapeutics, cCAM

– Biotechnology Incubator – Government sponsored

— Advanced applied Research: Leveraging cultures of Innovations and Entrepreneurship

– Fund announced 4/2011 OrbiMed – $222M 4.5x Leverage Gov. commitment by OrbiMed

– PPPP – Public, Private, Philanthropy

Adaption to Change is critical not the smartest will survive

  • Chaired by: 

Beth Jacobs, Managing Partner, Excellentia Global Partners

– complicated approaches of Scientific Collaborations

– Building Trust is it difficult?

– Tech transfer is having a bad rap

– Pharma tried avenues for efficiencies, Scientists in BIOTECH many are from Pharma, now their inventions go back to Pharma


  • Ora Dar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, Israel – $70M gov. Budget

– all gov. funding must by in conjunction with Private investment and commercialization ideas

– small companies needs IP to raise funding. University owns and license it to investors collaborations is in place

– Weitzman institute: antibodies platform, $17Billion sales

  • Chris Maggos, Consultant, Business Development, Alpine Institute for Drug Discovery – Not for profit

– Platform development in Academia is allowing the University to maintain equity on Projects, Oversight from Pharma is important for the know how of the industrial process

– Trust will appear quickly after relationships are established

– Tech Transfer has a role to serve the Public, Europe Universities different than US Universities

  • Edwin Constable, Head of Research, Professor of Chemistry at the University of Basel and Project leader and Member of the Management Board within the SNI, University of Basel

– Universities have different  responsibilities, public who fund Universities,juggle basic research and considering Pipeline of molecules, as a University the public good is different than a compound in a big Pharma, IP of university need be protected, identify drugs, collaborate with Hospitals for Clinical Trials

– IP need belong to the University but maintaining the IP and Protecting it may not be sensible.

– Primary PI has an idealist view of the World

– Universities need a new culture of entrepreneurship, failure in Academia is dreadful, not in Industry, risk taking need augmentations in Universities

– PPPP – three partners: Philanthropy – Gov. Axis is interesting

– disappointment – the role benefit for the Patient, drug distribution need be in place

– Translational model is the only proven others are correct and incorrect at the same time

– Monetizing IP:

– Translational Industry is in transition, where is it going?

  • Florian Schoedel, MD, PhD, Owner, PhilImmune, LLC ex-Merck

– collaborations: Gov. and Biotech – start up can reach maturity. de-bridging goals, product concept in Biotech, if Gov. funding ends, no continuation of the idea pipeline

– translation of research, big Foundations, i.e., Gates Foundation, found the right way to fund research and commercialize drugs as vaccine and deploy at needy markets in underdeveloped countries

– PI needs often a change of mind, steps they do not know, Chem Engineering vs Chemistry major, i.e,

– Research dept inside Pharma changed very much, cheaper innovations from Academia and from Biotech – efficiencies are needed

  • Maina Bhaman, Director, Healthcare Ventures, Imperial Innovations – Publicly listed

– Commercialization process and collaboration requires alignment, upfront time investment

– Transfer of IP, business that develop the molecule, then too much emphasis is placed on early IP

– Agrees, trust building is not easy

  • Prem Das, Chief Research Business Development Officer and heads DFCI’s Office of Research and Technology Ventures (ORTV), Dana-Farber Cancer Institute (DFCI)

– Bio marker driven, cost consideration

– Diagnostics in Cancer – DGCI – is in competition with Foundations in the DIagnostics

– Infrastructure to develop the chemistry platform

– Gov funded research IP is owned by the Institution not by the Gov.

– Early stage IP: non-exclusive licensing

– Trust between the investigator and the commercializing entity, change attitude of PI needed, to make it work, the Scientists who is on a Journey

– gap exists in Academic mind vs industry

– R&D centers run by Scientists, Office of Innovation go to Scientists for solutions

QUESTION fro the audience

– Failure in Drug Development, why?










Read Full Post »

10:00AM – 10/1/2014: Partnering II @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London


Real Time Media Conference Coverage  –  Business and Scientific Channels: Aviva Lev-Ari, PhD, RN @



Co-Chaired by: 

  • Fintan Walton, CEO and Founder, PharmaVentures

– is it more expensive to auction?

– secrative negotiation, if successful, structure deal and terms to following – dynamics with uncertainty

  • Stephanie Leousson, Principal, Torreya Partners

Panel is asked describe investment strategies

– new strategies: geographic, going public

– past: equity in IPO, at present long tern relations to offset costs, as the price will go up

10:00AM Partnering II – Deal Making: The Evolving Landscape of Deal Terms

  • Carlos de Souza, Chief Business Officer, to-BBB

– Name chance to BBB Therapeutics, based in Netherland, BRAIN products, tumors, neural degeneration and MS.

– License or go to Public market

– partner need to bring a significant value, develop product in co-development – an alternative

– what type of deals will bering the recognition of value via selection of compaounds, win-win, cooperation and keeping the product in the pipelin

– small biotech clinical compounds and some pre-clinical: Plans to go to public market, requires years of preparation per schedule

  • Corina Savill, Head BD&L Novartis Pharma AG

– trends: 7Billion in Acquisition, deals, BIOTECH high valuation in last two years, Private market has higher pricing

– Public Market Choices: acquisition by Big Pharma via IPO and then do a deal, Avista, geographic deal, win-win, Alphatech MAD,

– Auctioneering since 2006 and continue to do such deals, Israeli Gene company – Auctioneer, proportion equiyt, company reach the level that transplant and acquision will follow. Expensive technology to develop, take Equity position in the company using auctions allowing to materialize an acquisition CONDITIONED that the technology matures per plan, maturation involve continual innovation

– Aid in Dialysis had success with IPO, no auction, An osteoporosis company – decision not to pursue OP then invest took place no further integration Plans,

– Companies running Corporate investment portfolios: allowing collaboration, numeration drives to the sky,

– licensing becomes harder than in the past, due to availability of alternative avenues for investment

– Cash value is an opportunity, acquisition need to help the company investing

– In a geographic licensing it will become an acquisition target, PERIOD needed to absorb the positioning

  • Lubor Gaal, Head of Europe Search & evaluation, Business Development BMS

– VCs some are very small following 2009, Deal to buy rather than integrate with development, staging acquision vs development of start ups — NEW landscape, late payment for VCs,

– both exist – Auctions of private companies

– first decision on Science then on Financials

– licensing and relationship:  right ot compound given, the reason to acquire a company for additional value

– companies flourish NOT in the original plan they were created

  • Luca Bolliger, VP and Group Licensing Director, RECORDATI S.A.

– In the 90s activity started, at present in 19 countries, integration PrimaryCare pursued by acquisition, move from PrimaryCare to become Global, risk profile across territories

– deals are not novelties, Upfront vs Royalties — not available to all companies, if you are not first in class less opportunity pools

  •  Philippe Lopes-Fernandes, Global Business Development, Merck Serono

– Outsourcing more that fully integration, NEW landscape smart decision are a must, sell alter is different than in the past — NO one can find the next Amgen

– Europe is the focus:

  •  Stuart Kay, Director Transactions, GlaxoSmithKline

– Access a network of connections, Source from Academia, run and manage is attractive, if not acquired, access to innovation can be yet maintained,

  •  QUESTION FROM THE AUDIENCE: Auction and Tax inversion any relations?
  • no







Read Full Post »

9:ooAM – 10/1/2014: Partnering I @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London


Real Time Media Conference Coverage  –  Business and Scientific Channels: Aviva Lev-Ari, PhD, RN @



Co-Chaired by: 


  • Fintan Walton, CEO and Founder, PharmaVentures

– Strategies and Tactics


  • Stephanie Leouzon, Principal, Torreya Partners


Panelists Partnering I: 


  • Andrew Mackie, Global External R&D, Eli Lilly and Company

– Innovations with researches, series of molecule, prescreening, if interesting found, licensing agreement, engagement on Chemistry

– technology may be too early for the company, 20% funding from fund, advice as well as advice on coumpound of interest at the company

– pathways for selection, pipeline

– Pre clinical innovation – integration of Molecule the study is done.

– process id length, negotiation takes years

  • Jason Coloma, Global Head Venture & Innovation at Roche Partnering, F. Hoffmannn La Roche

– Oncology is Prime, structural include Genetech, contributes on Research, Access a and speed, business development in therapeutics. Venture Innovation is discovering pipeline, crossroad, partnership with VC, diversify biology, VC and non investment in area unless internal capabilities are existing,

– Which approach you are more proud of: early stage innovation, BIOTECH & VC, partnerships, value from working with Academics, Story of Scientist and building the relations takes time

  • Johan Verbeeck, Senior Director Alliance Management, J&J Innovation Center, Janssen Pharmaceutical of J&J

– Diagnostics, Pharmaceutical, growth from acquisition, 54% of pipeline are from external. Access to assets among big Pharma

– SF, Shanghai, Boston,

– presence and responsiveness and why the deal is not right

– Government and internal R&D are very important, internal R&D involves making calls on new directions

– North America is different that Europe, great good science in Europe, no risk taking. In USA, Kendall Square — risk is been taken 5 start ups over night.

– Question from the Floor: Scouts in Europe working on J&J Innovations from Spain to 8 countries in Europe,

– Satellite in Israel and in Moscow

– there are institutes for Drug Discoveries – collaboration with Pharma

– 25% from Academia, 50% partnership with industry  San Diego is a Hub

– Signing deals series of approval, university has funds and Pharma provide funds

– Some scientists can’t answer questions from Pharma

  • Frank Grams, VP, Head R&D Alliance Management & Contracting, Sanofi

– Sonafi more than 300 acquisitions, different company at present, process of integration, alliance with other industry and study from other Pharma, selling the opportunity in house, all Pharmaceutical in Sanofi: Diabetes, CVD, Opthalmonogy, OTC, Generic,

– Diabetes focus with therapeutics areas,investment in early stage all spectrum, academic alliance, pipeline, external sources, highly dependent on external world

– constant improvement

– right people to delegate, scouts, lawyer, communication – How do you create links to R&D? Structure organizational to allow for buyout.

– 80 and more collaborations, agreement with Academia in the US – outocme was almost zero, at present academic alliances must fit with strategy of Sanofi, look at it as a portfolio, getting out must be an option

  • Paola Casarosa, Corp. Vice President of Therapeutic Alliances and astrategic Partnerships, Boehringer Ingelheim

– CNS, Oncology, Immunology – How the portfolio looks and How to achieve,

– Internal vs. External — not invented here — not acceptable, integration of internal and external is in implementation, Fundamental in scouting, engagement with academia, BD acts Globally Boston, CHina, Japan, Deals – early partnering is very important to reach agreement early on

– colliding new target concepts, major effort on scouting in Academia, they are interested in external relation, No IP driven compound, but idea with innovation solution, investing in opportunities allowing foot in the door as first mover advantage

– depression, circuits of Brain — innovation

– people level very important

– Alliance reporting to R&D  – growing wiht project, supporter of this integration

– Japan support of Academia and Industry at the national level

  • Tomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk

– new perspective on Diabetes and Obesity, Retinopathie, Hemopealia, Growth Disorder, advice on early stage research, establish repationship with PI and where PI, postdocs are moving. 60% Innovations in DIabetes from the US, face to face meeting, scientific Forums

– Integration with R&D Obesity as a complication of Diabetes, gate relations, Academia sees Pharma as friend, entrepreneurship from Academia — new direction – this is the successful adoptation






Read Full Post »

« Newer Posts - Older Posts »